NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care options and outcomes for patients with neurological disorders, announced today its participation in two upcoming medical industry conferences. The company will attend the American Epilepsy Society (AES) 2025 Annual Meeting in Atlanta, GA, from December 5th to December 9th, and the CNS Drug Delivery Summit in Boston, MA, from December 9th to 11th.
The AES Annual Meeting, as detailed on the conference website, brings together healthcare providers, scientists, advocates, industry professionals, and others dedicated to improving outcomes for people with epilepsy. This event provides a platform for NeuroOne to showcase its minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation.
The CNS Drug Delivery Summit, accessible via its conference website, convenes over 100 industry experts, including neuroscientists, chemists, device engineers, and delivery specialists. The summit focuses on cutting-edge strategies to address the unique challenges of gaining access to the brain for therapeutic purposes. NeuroOne's participation underscores its commitment to advancing treatments for neurological disorders such as epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries.
NeuroOne's technology aims to improve patient outcomes and reduce procedural costs. The company may also pursue applications for depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information about NeuroOne, visit the company's website at nmtc1.com.
